Literature DB >> 12520710

bcl-2 expression by multicolor flow cytometric analysis assists in the diagnosis of follicular lymphoma in lymph node and bone marrow.

James R Cook1, Fiona E Craig, Steven H Swerdlow.   

Abstract

The expression of bcl-2, CD10, and CD20 was examined by multicolor flow cytometry in 78 samples including lymph node or other tissue biopsy specimens containing follicular lymphoma (FL; n = 17), reactive hyperplasia (RH; n = 28), or other malignant lymphomas (n = 20), as well as bone marrow aspirates (n = 13). The presence of CD10+ cells with high bcl-2 expression predicted the presence of FL rather than RH with a positive predictive value of 100% and negative predictive value of 96%. CD10+ cells with high bcl-2 expression also were found in a subset of diffuse large B-cell lymphomas and were otherwise rare in other types of malignant lymphoma. In contrast with immunohistochemical studies, a reduced but apparently measurable level of bcl-2 was present in benign follicular center cells. Hematogones showed lower bcl-2 levels than did FL cells in the bone marrow, and neutrophils were bcl-2-. Measurement of bcl-2 expression levels by multiparameter flow cytometry offers a rapid, quantitative assessment that may assist in the diagnosis of FL in lymph nodes or bone marrow, even when other CD10+ cells or admixed normal B cells are present.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12520710     DOI: 10.1309/820R-476K-Y9G0-3L9A

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

2.  Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.

Authors:  Ikuo Matsuda; Seiichi Hirota
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies.

Authors:  Raju K Pillai; Urvashi Surti; Steven H Swerdlow
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

4.  A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Authors:  Thomas J Kipps; Herbert Eradat; Sebastian Grosicki; John Catalano; Walter Cosolo; Iryna S Dyagil; Sreeni Yalamanchili; Akiko Chai; Srikumar Sahasranaman; Elizabeth Punnoose; Deborah Hurst; Halyna Pylypenko
Journal:  Leuk Lymphoma       Date:  2015-05-12

5.  Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia.

Authors:  Rachel L Sargent; Fiona E Craig; Steven H Swerdlow
Journal:  Int J Clin Exp Pathol       Date:  2009-06-16

6.  Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas?

Authors:  Andreja Brozic; Ziva Pohar Marinsek; Srdjan Novakovic; Veronika Kloboves Prevodnik
Journal:  Diagn Pathol       Date:  2015-10-20       Impact factor: 2.644

7.  Flow Cytometric Evaluation of Double/Triple Hit Lymphoma.

Authors:  Christine G Roth; Amanda Gillespie-Twardy; Stanley Marks; Mounzer Agha; Anastasios Raptis; Jing-Zhou Hou; Rafic Farah; Yan Lin; Ying Qian; Liron Pantanowitz; Michael Boyiadzis
Journal:  Oncol Res       Date:  2016       Impact factor: 5.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.